HIV Drugs Market Size, Share, Trends, Analysis, Report: By Medication Class: Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Others; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    HIV Overview 
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    HIV Epidemiology Analysis – 8 Major Markets
    5.1    8MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States HIV Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom HIV Epidemiology Forecast (2017-2032)
        5.3.1    Germany HIV Epidemiology Forecast (2017-2032)
        5.3.2    France HIV Epidemiology Forecast (2017-2032)
        5.3.3    Italy HIV Epidemiology Forecast (2017-2032)
        5.3.4    Spain HIV Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom HIV Epidemiology Forecast (2017-2032)
    5.4    Japan HIV Epidemiology Forecast (2017-2032)
6    HIV Drugs Market Overview – 8 Major Markets 
    6.1    HIV Drugs Market Historical Value (2017-2023) 
    6.2    HIV Drugs Market Forecast Value (2024-2032)
7    HIV Drugs Market Landscape – 8 Major Markets 
    7.1    HIV Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    HIV Drugs: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Medication Class
8    HIV Drugs Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    HIV Drugs Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    HIV Drugs Market Segmentation-8 Major Markets 
    11.1    HIV Drugs Market by Medication Class
        11.1.1    Market Overview
        11.1.2    Multi-Class Combination Drugs
        11.1.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        11.1.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        11.1.5     Protease Inhibitors (PIs)
        11.1.6    Entry Inhibitors
        11.1.7    HIV Integrase Strand Transfer Inhibitors
        11.1.8    Others
    11.2    HIV Drugs Market by Distribution Channel
        11.2.1    Market Overview
        11.2.2    Hospital Pharmacies
        11.2.3    Drugs stores and retail pharmacies
        11.2.4    Online pharmacies
    11.3    HIV Drugs Market by End User
        11.3.1    Market Overview
        11.3.2    Hospitals 
        11.3.3    Clinics
        11.3.4    Others
    11.4    HIV Drugs Market by Region
        11.4.1    Market Overview
        11.4.2    United States
        11.4.3    EU-4 and the United Kingdom
            11.4.3.1    Germany
            11.4.3.2    France
            11.4.3.3    Italy
            11.4.3.4    Spain
            11.4.3.5    United Kingdom
        11.4.4    Japan
        11.4.5    China
12    United States HIV Drugs Market
    12.1    HIV Drugs Market Historical Value (2017-2023) 
    12.2    HIV Drugs Market Forecast Value (2024-2032)
    12.3    United States HIV Drugs Market by Medication Class
        12.3.1    Market Overview
        12.3.2    Multi-Class Combination Drugs
        12.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        12.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        12.3.5     Protease Inhibitors (PIs)
        12.3.6    Entry Inhibitors
        12.3.7    HIV Integrase Strand Transfer Inhibitors
        12.3.8    Others
    12.4    United States HIV Drugs Market by Distribution Channel
        12.4.1    Market Overview
        12.4.2    Hospital Pharmacies
        12.4.3    Drugs stores and retail pharmacies
        12.4.4    Online pharmacies 
13    EU-4 and United Kingdom HIV Drugs Market
    13.1    EU-4 and United Kingdom HIV Drugs Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom HIV Drugs Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom HIV Drugs Market Overview
    13.4    EU-4 and United Kingdom HIV Drugs Market by Medication Class
        13.4.1    Market Overview
        13.4.2    Multi-Class Combination Drugs
        13.4.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        13.4.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        13.4.5     Protease Inhibitors (PIs)
        13.4.6    Entry Inhibitors
        13.4.7    HIV Integrase Strand Transfer Inhibitors
        13.4.8    Others
    13.5    EU-4 and United Kingdom HIV Drugs Market by Distribution Channel
        13.5.1    Market Overview
        13.5.2    Hospital Pharmacies
        13.5.3    Drugs stores and retail pharmacies
        13.5.4    Online pharmacies 
14    Japan HIV Drugs Market
    14.1    Japan HIV Drugs Market Historical Value (2017-2023) 
    14.2    Japan HIV Drugs Market Forecast Value (2024-2032)
    14.3    Japan HIV Drugs Market by Medication Class
        14.3.1    Market Overview
        14.3.2    Multi-Class Combination Drugs
        14.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        14.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        14.3.5     Protease Inhibitors (PIs)
        14.3.6    Entry Inhibitors
        14.3.7    HIV Integrase Strand Transfer Inhibitors
        14.3.8    Others
    14.4    Japan HIV Drugs Market by Distribution Channel
        14.4.1    Market Overview
        14.4.2    Hospital Pharmacies
        14.4.3    Drugs stores and retail pharmacies
        14.4.4    Online pharmacies 
15    China HIV Drugs Market
    15.1    China HIV Drugs Market Historical Value (2017-2023) 
    15.2    China HIV Drugs Market Forecast Value (2024-2032)
    15.3    China HIV Drugs Market by Medication Class
        15.3.1    Market Overview
        15.3.2    Multi-Class Combination Drugs
        15.3.3    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        15.3.4    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        15.3.5     Protease Inhibitors (PIs)
        15.3.6    Entry Inhibitors
        15.3.7    HIV Integrase Strand Transfer Inhibitors
        15.3.8    Others
    15.4    China HIV Drugs Market by Distribution Channel
        15.4.1    Market Overview
        15.4.2    Hospital Pharmacies
        15.4.3    Drugs stores and retail pharmacies
        15.4.4    Online pharmacies 
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    ViiV Healthcare Group of Companies 
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisitions
        22.1.5    Certifications
    22.2    Gilead Sciences, Inc.  
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    GSK Plc. 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Merck & Co., Inc. 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    Bristol-Myers Squibb Company 
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Johnson & Johnson Services, Inc. 
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Boehringer Ingelheim International GmbH 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    AbbVie Inc. 
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Genentech, Inc. 
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Mylan N.V. 
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    CytoDyn Inc. 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications
    22.12    Daichii Sankyo Company, Limited 
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications
    22.13    Pfizer Inc.  
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications
    22.14    Shantou Huatai Pharmaceutical Co., Ltd. 
        22.14.1    Financial Analysis
        22.14.2    Product Portfolio
        22.14.3    Demographic Reach and Achievements
        22.14.4    Mergers and Acquisitions
        22.14.5    Certifications
    22.15    Shengzhen Chongway Biotechnology Co., Ltd
        22.15.1    Financial Analysis
        22.15.2    Product Portfolio
        22.15.3    Demographic Reach and Achievements
        22.15.4    Mergers and Acquisitions
        22.15.5    Certifications
List not exhaustive
23    HIV Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)
    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.